

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

NCT05670951

Status	RECRUITING
Phase	Phase 3
Sponsor	Elgan Pharma Ltd.
Enrollment	360 participants

Key Eligibility Criteria

Inclusion (3)

- Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (± 2 weeks) between maternal dates and/or early antenatal ultrasound
- Birth weight ≥ 500 g
- Singleton or twin birth

Exclusion (1)

- \-

Locations (1 total)

Laniado Hospital, Netanya, Israel